OncoMatch/Clinical Trials/NCT05749289
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Is NCT05749289 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Al18F-octreotide for neuroendocrine tumor.
Phase 2/3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05749289Data as of Jun 2026Location: China
Treatment: Al18F-octreotide — This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Al18F-octreotide
Cancer type
Neuroendocrine Tumor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05749289 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages